Clinical Significance Of The Level Of Serum S HLA-I In Patients With Hematologic Malignancies

Objective To study the clinical significance of the level of serum soluble human leukocyte antigensⅠ(sHLA-Ⅰ) in patients with acute leukemia, lymphoma and multiple myeloma.Method Concentrations of serum sHLA-Ⅰin 144 patients with acute leukemia, lymphoma and multiple myeloma were determined by enzyme linked immunosorbent assay (ELISA).Results The level of serum sHLA-Ⅰin acute leukemia patients was (1.3011±0.7779)μg/ml, and multiple myeloma (1.6659±0.7117)μg/ml,. lymphoma (1.7636±0.7708)μg/ml, normal control (0.6836±0.3756)μg/ml, untreated (1.7291±0.8365)μg/ml, relapsing (1.6307±0.7225)μg/ml, the complete remission(CR) (0.8334±0.4502)μg/ml. Concentrations of serum sHLA-I in acute leukemia, lymphoma and multiple myeloma patients were significantly increased compared with normal control(P<0.05). Lymphoma and multiple myeloma patients had significantly higher levels of sHLA-1 than acute leukemia subjects (P<0.05),but no difference was detected between lymphoma and multiple myeloma (P>0.05). sHLA-1 levels were significantly higher in untreated and relapsing patients than in the complete remission(CR) subjects (P<0.05), while did not differ significantly between the untreated and relapsing patients (P>0.05). The serum level of sHLA-I was closely correlated with the peripheral leukocytes and contents of serum LDH,as well asβ2 Microglobulin (β2-M).Conclusions Concentrations of serum sHLA-Ⅰin hematological malignancy were significantly increased compared with normal control.These results indicate that the quantification of serum sHLA-I levels seems to help in the evaluation of the patients with acute leukemia, lymphoma and multiple myeloma.